Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C

Hepatology

Volumn 42, Issue 1, 2005, Pages 104-112

  Cox, Andrea L ^a   Mosbruger, Timothy ^a   Lauer, Georg M ^b   Pardoll, Drew ^a   Thomas, David L ^a   Ray, Stuart C ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; POLYPROTEIN;

ADULT; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; VIREMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEPATITIS C; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 21344442371     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20749     Document Type: Article

References (55)

1. World Health Organization. Hepatitis C: global prevalence. Weekly Epidemiological Record 1997;72:341-348.
2. Alter MJ. Epidemiology of hepatitis C. HEPATOLOGY 1997;26(3 Suppl 1):62S-65S.
3. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15:5-14.
4. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb Mortal Wkly Rep 1998;47:1-39.
5. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999;29:908-914.
6. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
7. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non- B hepatitis. N Engl J Med 1991;325:98-104.
8. Bartera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. HEPATOLOGY 1995;21:639-644.
9. Garson JA, Tuke PW, Makris M, Briggs M, Machin SJ, Preston FE, et al. Demonstration of viraemia patterns in haemophiliacs treated with hepatitis C virus contaminated factor VIII concentrates. Lancet 1990;336:1022-1025.
10. Prince AM, Brotman B, Inchauspe G, Pascual D, Nasoff M, Hosein B, et al. Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis. J Infect Dis 1993;167:1296-1301.
11. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194(10):1395-1406.
12. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-449.
13. Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-1536.
14. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
15. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-582.
16. Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. HEPATOLOGY 1997;25:705-712.
17. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996;98:1432-1440.
18. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995;95:521-530.
19. He XS, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999;96(10):5692-5697.
20. Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994;68:3334-3342.
21. Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995;69:2462-2470.
22. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550-5558.
23. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000;30:2479-2487.
24. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S11-S19.
25. Liu Z, Netski DM, Mao Q, Laeyendecker O, Ticehurst JR, Wang XH, et al. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol 2004;42:4223-4229.
26. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000;182:698-707.
27. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. Multiple sequence alignment with Clustal X. Trends Biochem Sci 1998;23:403-405.
28. Hall TA. BioEdit: biological sequence alignment editor for Windows 95/98/NT version 5.0.7. software 2001; Distributed by author: http://www. mbio.ncsu.edu/RNaseP/info/programs/BIOEDIT/bioedit.html.
29. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998;14:817-818.
30. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39:783-791.
31. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad DC, et al. Prospective evaluation of community-acquired acute Hepatitis C. Clin Infect Dis 2004;40:951-958.
32. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002;76:6104-6113.
33. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002;128:195-203.
34. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-172.
35. Wang YM, Ray SC, Laeyendecker O, Ticehurst JR, Thomas DL. Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single- and double-stranded DNAs. J Clin Microbiol 1998;36: 2982-2989.
36. Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherry PC. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 1991;174: 875-880.
37. Hou S, Doherry PC, Zijlstra M, Jaenisch R, Katz JM. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells. J Immunol 1992;149:1319-1325.
38. Koup RA, Safrit JA, Cao Y, Andrew CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650.
39. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000;407:386-390.
40. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang X-H, Yang H-C, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005;201:1741-1752.
41. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002;169: 3447-3458.
42. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-895.
43. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001;193:181-194.
44. McGinn TM, Wei Q, Stallworth J, Fultz PN. Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques. AIDS Res Hum Retroviruses 2004;20:443-456.
45. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. HEPATOLOGY 2003;38: 1437-1448.
46. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001;120:512-524.
47. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999;162: 5584-5591.
48. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394:482-485.
49. Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993;178:17-25.
50. Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003;77:862-870.
51. Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Ryder S, Ball JK, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001;31:2388-2394.
52. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-2204.
53. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
54. Freeman AJ, French RA, Post JJ, Harvey CE, Gilmour SJ, White PA, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004;190:1093-1097.
55. Mizukoshi E, Eisenbach C, Edlin B, Weiler C, Carrington M, O'Brien T, et al. HCV-specific cellular immune responses in subjects who are anti-HCV-negative, HCV RNA-negative despite long term (> 15 years) injection drug use (AASLD Annual Meeting 2003 abstract #111). HEPATOLOGY 2003;38(Suppl):210A.